Management dilemma in choosing evolving treatments in neutropenic septic shock.
How does a physician decide to use a recently FDA-approved life-saving device in a desperately ill child in which little prior clinical experience is available? This report presents a pediatric patient with neutropenic septic shock and multiorgan failure (MOF) with a 95% chance of death and the avai...
| Publicado en: | Pediatric Nephrology Vol. 40; no. 11; pp. 3577 - 3584 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | case study pictorial tables/charts Journal Article |
| Publicado: |
Springer Nature
Nov2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |